Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO Annual Meeting.The ...

Perjeta (pertuzumab) is already available for use in HER-2 positive patients with metastatic breast cancer when combined with Herceptin and docetaxel, but is only available through the Cancer ...

The Best of ASCO UAE Conference 2025, organised by SEHA, part of PureHealth Group, in collaboration with Tawam Hospital, ...

CHICAGO -- First-line trastuzumab deruxtecan (T-DXd) combined with pertuzumab (Perjeta) improved progression-free survival (PFS) in HER2-positive locally advanced or metastatic breast cancer ...

Since I’m still in the dark about how much my next 13 Herceptin infusions will cost in total, I decided to withdraw some of my EPF money “just in case”. It ...

The pathology report from my surgery, from testing the lesion and lymph nodes removed, show no residual cancer. I knew the odds of this happening was only 50/50 because hormone-positive tumours don't ...

Tolaney will present the most anticipated results for Monday with DESTINY-Breast09 (NCT04784715), which compares T-DXd with or without pertuzumab (Perjeta) against a taxane chemotherapy ...

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.